$160 million ‘moonshot’ backs Boston effort to revolutionize rare disease treatment - The Boston Globe

What the report says

The Boston Globe reports that the Broad Institute, Boston Children’s Hospital and Maine-based Jackson Laboratory announced a new nonprofit collaboration Tuesday aimed at developing gene therapies for rare diseases while lowering barriers to access. The Center for Therapeutic Genetics is backed by an effort tied to ARPA-H, the federal health research “moonshot” agency, which recently said it would spend up to $160 million to advance customized gene-editing treatments for several rare diseases.

According to the Globe, the center plans to build precision medicines and share methods, data and training with clinicians so similar treatments can be replicated beyond one-off research projects. Dr. Winston Yan, the center’s founding director, described a long-term goal of making personalized genetic treatment function more like a standard clinical procedure, rather than requiring families to raise large sums and coordinate individually with scientists.

The initial work will focus on precision gene-editing therapies for children with rare genetic epilepsies. Dr. Timothy Yu of Boston Children’s, one of the founding partners, said the model is intended to support the broader field through philanthropy and strategic selection of conditions, not to create a family-funded queue for specific diseases. The announcement also said the center is still in a founding phase and is not yet taking patient referrals or offering clinical care.

The need is significant: the Globe cites the National Organization for Rare Disorders as saying one in 10 Americans has a rare disease, about half of them children, while fewer than 5 percent of more than 10,000 known rare diseases have approved treatments. Advocates and specialists told the Globe the collaboration could help create repeatable systems, though safely scaling access remains a challenge no single institution can solve alone.